151 related articles for article (PubMed ID: 27436099)
1. Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study.
Wiebe S; Schnell D; Külzer R; Gansser D; Weber A; Wallenstein G; Halabi A; Conrad A; Wind S
Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):461-469. PubMed ID: 27436099
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.
Schnell D; Buschke S; Fuchs H; Gansser D; Goeldner RG; Uttenreuther-Fischer M; Stopfer P; Wind S; Petersen-Sylla M; Halabi A; Koenen R
Cancer Chemother Pharmacol; 2014 Aug; 74(2):267-75. PubMed ID: 24906422
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours.
Wind S; Schmid M; Erhardt J; Goeldner RG; Stopfer P
Clin Pharmacokinet; 2013 Dec; 52(12):1101-9. PubMed ID: 23813493
[TBL] [Abstract][Full Text] [Related]
4. Effect of Renal Impairment on the Pharmacokinetics of Pradigastat, a Novel Diacylglycerol Acyltransferase1 (DGAT1) Inhibitor.
Mita S; Meyers D; Pal P; Lin T; Majumdar T; Rebello S; Sunkara G; Chen J
Clin Pharmacokinet; 2015 Jul; 54(7):751-60. PubMed ID: 25627776
[TBL] [Abstract][Full Text] [Related]
5. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.
Stangier J; Rathgen K; Stähle H; Mazur D
Clin Pharmacokinet; 2010 Apr; 49(4):259-68. PubMed ID: 20214409
[TBL] [Abstract][Full Text] [Related]
6. Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination.
Allen A; Davis A; Hardes K; Tombs L; Kempsford R
Clin Ther; 2012 Dec; 34(12):2316-32. PubMed ID: 23200625
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment.
Jin F; Robeson M; Zhou H; Hisoire G; Ramanathan S
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1133-41. PubMed ID: 26526983
[TBL] [Abstract][Full Text] [Related]
8. Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.
Wind S; Schnell D; Ebner T; Freiwald M; Stopfer P
Clin Pharmacokinet; 2017 Mar; 56(3):235-250. PubMed ID: 27470518
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the single-dose pharmacokinetics of bilastine in subjects with various degrees of renal insufficiency.
Lasseter KC; Sologuren A; La Noce A; Dilzer SC
Clin Drug Investig; 2013 Sep; 33(9):665-73. PubMed ID: 23873362
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer.
Cappuzzo F; Finocchiaro G; Grossi F; Bidoli P; Favaretto A; Marchetti A; Valente ML; Cseh A; Clementi L; Massey D; Santoro A
J Thorac Oncol; 2015 Apr; 10(4):665-72. PubMed ID: 25514804
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
Suder A; Ang JE; Kyle F; Harris D; Rudman S; Kristeleit R; Solca F; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J; Spicer J
Eur J Cancer; 2015 Nov; 51(16):2275-84. PubMed ID: 26296295
[TBL] [Abstract][Full Text] [Related]
12. The effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegol.
Bui K; She F; Sostek M
J Clin Pharmacol; 2014 Dec; 54(12):1375-82. PubMed ID: 24946021
[TBL] [Abstract][Full Text] [Related]
13. Impact of Renal Impairment on the Pharmacokinetics of Apremilast and Metabolite M12.
Liu Y; Zhou S; Assaf M; Nissel J; Palmisano M
Clin Pharmacol Drug Dev; 2016 Nov; 5(6):469-479. PubMed ID: 27870479
[TBL] [Abstract][Full Text] [Related]
14. A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function.
Ermer J; Corcoran M; Lasseter K; Marbury T; Yan B; Martin PT
Ther Drug Monit; 2016 Aug; 38(4):546-55. PubMed ID: 26926668
[TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetics and safety of darapladib in subjects with severe renal impairment.
Magee MH; Shaddinger B; Collins D; Siddiqi S; Soffer J
Br J Clin Pharmacol; 2015 Oct; 80(4):654-61. PubMed ID: 25953363
[TBL] [Abstract][Full Text] [Related]
16. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
Soria JC; Felip E; Cobo M; Lu S; Syrigos K; Lee KH; Göker E; Georgoulias V; Li W; Isla D; Guclu SZ; Morabito A; Min YJ; Ardizzoni A; Gadgeel SM; Wang B; Chand VK; Goss GD;
Lancet Oncol; 2015 Aug; 16(8):897-907. PubMed ID: 26156651
[TBL] [Abstract][Full Text] [Related]
17. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers.
Stopfer P; Marzin K; Narjes H; Gansser D; Shahidi M; Uttereuther-Fischer M; Ebner T
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1051-61. PubMed ID: 22200729
[TBL] [Abstract][Full Text] [Related]
18. Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment.
Sidharta PN; Ulč I; Dingemanse J
Clin Drug Investig; 2019 Nov; 39(11):1117-1123. PubMed ID: 31435905
[TBL] [Abstract][Full Text] [Related]
19. A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment.
Tayo B; Taylor L; Sahebkar F; Morrison G
Clin Pharmacokinet; 2020 Jun; 59(6):747-755. PubMed ID: 31802404
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.
Townsend RW; Akhtar S; Alcorn H; Berg JK; Kowalski DL; Mujais S; Desai AV
Eur J Clin Pharmacol; 2017 Jun; 73(6):669-678. PubMed ID: 28271239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]